书签 分享 收藏 举报 版权申诉 / 49
上传文档赚钱

类型支气管哮喘课件(同名22).ppt

  • 上传人(卖家):晟晟文业
  • 文档编号:4587389
  • 上传时间:2022-12-22
  • 格式:PPT
  • 页数:49
  • 大小:4.52MB
  • 【下载声明】
    1. 本站全部试题类文档,若标题没写含答案,则无答案;标题注明含答案的文档,主观题也可能无答案。请谨慎下单,一旦售出,不予退换。
    2. 本站全部PPT文档均不含视频和音频,PPT中出现的音频或视频标识(或文字)仅表示流程,实际无音频或视频文件。请谨慎下单,一旦售出,不予退换。
    3. 本页资料《支气管哮喘课件(同名22).ppt》由用户(晟晟文业)主动上传,其收益全归该用户。163文库仅提供信息存储空间,仅对该用户上传内容的表现方式做保护处理,对上传内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知163文库(点击联系客服),我们立即给予删除!
    4. 请根据预览情况,自愿下载本文。本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
    5. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007及以上版本和PDF阅读器,压缩文件请下载最新的WinRAR软件解压。
    配套讲稿:

    如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。

    特殊限制:

    部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。

    关 键  词:
    支气管哮喘 课件 同名 22
    资源描述:

    1、支气管哮喘支气管哮喘Bronchial AsthmaOutlinen Burden of Asthma n Definition of Asthman Etiology and Mechanismn Diagnosis and Classificationn Asthma Medicationsn Asthma management and PreventionBurden of AsthmanHealth care expenditures very highnDeveloped economies might expect to spend 1-2 percent of total hea

    2、lth care expenditures on asthma.Developing economies likely to face increased demandnPoorly controlled asthma is expensive;investment in prevention medication likely to yield cost savings in emergency careAsthma Prevalence and MortalityEpidemiology of AsthmaProportion of population with asthma(%)Cas

    3、e fatality rate per 100,000 asthmaticsDefinition of AsthmanA chronic inflammatory disorder of the airwaysnMany cells and cellular elements play a rolenChronic inflammation is associated with airway hyperresponsiveness that leads to recurrent episodes of wheezing,breathlessness,chest tightness,and co

    4、ughingnWidespread,variable,and often reversible airflow limitationMechanismsAsthma InflammationAsthma InflammationRisk Factors for AsthmanHost factors:predispose individuals to,or protect them from,developing asthmanEnvironmental factors:influence susceptibility to development of asthma in predispos

    5、ed individuals,precipitate asthma exacerbations,and/or cause symptoms to persistFactors that Influence Asthma Development and ExpressionHost Factors Genetic -Atopy -Airway hyperresponsiveness Gender ObesityEnvironmental Factorsn Indoor allergensn Outdoor allergensn Occupational sensitizersn Tobacco

    6、smoken Air pollutionn Respiratory Infectionsn DietMajor Indoor Asthma TriggersIs it Asthma?nRecurrent episodes of wheezingnTroublesome cough at nightnCough or wheeze after exercisenCough,wheeze or chest tightness after exposure to airborne allergens or pollutantsnColds“go to the chest”or take more t

    7、han 10 days to clearAsthma Diagnosisn History and patterns of symptoms-Episodic symptoms after an incidental allergen exposure,seasonal variability of symptoms;-Positive family history of asthma and atopic disease;-Symptoms improved by appropriate asthma treatment;n Physical examination-May be norma

    8、l;-The most usual abnormal physical finding is wheezing on auscultation;Asthma DiagnosisnMeasurements of lung function -Spirometry -Peak expiratory flownMeasurement of airway responsiveness nMeasurements of allergic status to identify risk factorsnExtra measures may be required to diagnose asthma in

    9、 children 5 years and younger and the elderlyTypical Spirometric(FEVTypical Spirometric(FEV1 1)TracingsTracingsTime(sec)FEV1VolumeNote:Each FEV1 curve represents the highest of three repeat measurementsMeasuring Variability of Peak Expiratory FlowMeasuring Airway ResponsivenessEtiologic Diagnosis Id

    10、entify environmental factors nAllergen challenge testnSkin prick testnSpecific IgEDifferential DiagnosisnOther forms of obstructive lung disease,particularly COPD nNon-respiratory causes of symptoms(e.g.,left ventricular failure)nNon-obstructive forms of lung disease(e.g.,diffuse parenchymal lung di

    11、sease)nUpper airway obstruction and inhaled foreign bodiesController MedicationsnInhaled glucocorticosteroidsnLeukotriene modifiersnLong-acting inhaled 2-agonistsnSystemic glucocorticosteroids nTheophyllinenCromonesnLong-acting oral 2-agonistsnAnti-IgEnSystemic glucocorticosteroidsEstimate Comparati

    12、ve Daily Dosages for Inhaled Glucocorticosteroids by AgeDrug Low Daily Dose(g)Medium Daily Dose(g)High Daily Dose(g)5 y Age 5 y Age 5 y Age 500-1000 200-400 1000 400Budesonide200-600 100-200 600-1000 200-400 1000 400 Budesonide-Neb Inhalation Suspension 250-500 500-1000 1000 Ciclesonide 80 160 80-16

    13、0 160-320 160-320 320-1280 320Flunisolide500-1000 500-750 1000-2000 750-1250 2000 1250 Fluticasone100-250 100-200 250-500 200-500 500 500 Mometasone furoate200-400 100-200 400-800 200-400800-1200 400Triamcinolone acetonide400-1000 400-800 1000-2000 800-1200 2000 1200 Reliever Medications Rapid-actin

    14、g inhaled 2-agonists Systemic glucocorticosteroids Anticholinergics Theophylline Short-acting oral 2-agonistsPharmacologic TherapynLong-term control medications corticosteroids inhaled form systemic steroids used to gain prompt control of disease when initiating inhaled tx Long-acting beta2-agonists

    15、 used concomitantly with anti-inflammatory meds for long-term symptom control especially nocturnal symptoms prevents exercise-induced bronchospasm Long-term control medications Leukotriene modifiers zafirlukast-leukotriene receptor antagonist zileuton-5-lipoxygenase inhibitor is alternative therapy

    16、to low doses of inhaled steroids/nedocromil/cromolyn alternative tx to low dose inhaled steroids/cromolyn/nedocromil recommended for 12yrs with mild persistent asthma.Further study neededPharmacologic TherapynQuick relief medications Short acting beta2-agonists-relief of acute symptoms Anticholinerg

    17、ics-may provide additive benefit to beta2 drugs in severe exacerbation.May be alternative to beta2-agonists Systemic steroids-moderate-to-severe persistent asthma in acute exacerbations or to prevent recurrence of exacerbationsPharmacologic TherapyTreatment/Long Term ControlnCorticosteroids Most pot

    18、ent and effective Reduction in symptoms,improvement in PEF and spirometry,diminished airway hyperresponsiveness,prevention of exacerbations,possible prevention of airway wall remodeling Suppresses:cytosine production,airway eosinophilic recruitment,chemical mediators nLong-acting beta-2 agonists Rel

    19、ax airway smooth muscle Duration of action 12 hrs Not used in acute exacerbations Adjunct to anti-inflammatory tx for long-term symptom control especially nocturnal symptomsTreatment/Long Term ControlnLeukotriene modifiers Leukotrienes are potent biochemical mediators released from mast cells,eosino

    20、phils,and basophils that:contract bronchial smooth muscle increase vascular permeability increase mucus secretions attract&activate inflammatory cells in airwaysTreatment/Long Term ControlAsthma Treatment/Quick ReliefnShort-acting beta2 agonists Relax airway smooth muscle and increase in airflow in

    21、1 canister/mo indicates inadequate control and indicates need to intensify anti-inflammatory tx Regularly scheduled use NOT recommendednAnticholinergics Cholinergic innervation important in regulation of airway smooth muscle tone Ipratropium bromide(quaternary derivative of atropine without its side

    22、 effects)Additive benefit with inhaled beta 2-agonists in severe asthma exacerbations Effectiveness in long-term management not demonstratedAsthma Treatment/Quick ReliefnSystemic steroids speed resolution of airflow obstruction reduce rate of relapsenMedications to reduce oral steroid dependence Tro

    23、leandomycin,cyclosporin,gold,methotrexate,IV immunoglobulin,dapsone,hydroxychloroquine Asthma Treatment/Quick ReliefAsthma Medication EquipmentMethods of Delivery nMedications may be given by:-Metered Dose Inhaler(MDI)-Dry Powdered Inhaler(DPI)-Nebulizer-OrallynImportant to review technique for all

    24、delivery methodsClinical Control of Asthma No(or minimal)*daytime symptoms No limitations of activity No nocturnal symptoms No(or minimal)need for rescue medication Normal lung function No exacerbations_*Minimal=twice or less per weekLevels of Asthma ControlCharacteristicControlled(All of the follow

    25、ing)Partly controlled(Any present in any week)Uncontrolled Daytime symptomsNone(2 or less/week)More than twice/week3 or more features of partly controlled asthma present in any weekLimitations of activitiesNoneAnyNocturnal symptoms/awakeningNoneAnyNeed for rescue/“reliever”treatmentNone(2 or less/we

    26、ek)More than twice/weekLung function(PEF or FEV1)Normal 80%predicted or personal best(if known)on any dayExacerbationNone One or more/year 1 in any weekGoals of Long-term ManagementnAchieve and maintain control of symptomsnMaintain normal activity levels,including exercisenMaintain pulmonary functio

    27、n as close to normal levels as possiblenPrevent asthma exacerbationsnAvoid adverse effects from asthma medicationsnPrevent asthma mortalitycontrolledpartly controlleduncontrolledexacerbationmaintain and find lowest controlling stepconsider stepping up to gain controlstep up until controlledtreat as

    28、exacerbationTREATMENT STEPSREDUCEINCREASESTEP1STEP2STEP3STEP4STEP5REDUCEINCREASE Exacerbations of asthma are episodes of progressive increase in shortness of breath,cough,wheezing,or chest tightness Exacerbations are characterized by decreases in expiratory airflow that can be quantified and monitor

    29、ed by measurement of lung function(FEV1 or PEF)Severe exacerbations are potentially life-threatening and treatment requires close supervisionManage Asthma ExacerbationsPrimary therapies for exacerbations:Repetitive administration of rapid-acting inhaled 2-agonist Early introduction of systemic gluco

    30、corticosteroids Oxygen supplementationClosely monitor response to treatment with serialmeasures of lung functionManage Asthma ExacerbationsAllergen-specific ImmunotherapynGreatest benefit of specific immunotherapy using allergen extracts has been obtained in the treatment of allergic rhinitisnThe ro

    31、le of specific immunotherapy in asthma is limitednSpecific immunotherapy should be considered only after strict environmental avoidance and pharmacologic intervention,including inhaled glucocorticosteroids,have failed to control asthmanPerform only by trained physicianSpecial ConsiderationsSpecial c

    32、onsiderations are required tomanage asthma in relation to:Pregnancy Surgery Rhinitis,sinusitis,and nasal polyps Occupational asthma Respiratory infections Gastroesophageal reflux Aspirin-induced asthma Anaphylaxis and Asthma1.Develop Patient/Doctor Partnership2.Identify and Reduce Exposure to Risk F

    33、actors3.Assess,Treat and Monitor Asthma4.Manage Asthma Exacerbations5.Special ConsiderationsAsthma Management and PreventionProgram:Five ComponentsRevised 2006nAsthma can be effectively controlled in most patients by intervening to suppress and reverse inflammation as well as treating bronchoconstri

    34、ction and related symptomsnAlthough there is no cure for asthma,appropriate management that includes a partnership between the physician and the patient/family most often results in the achievement of controlAsthma Management and Prevention Program:Summary A stepwise approach to pharmacologic therapy is recommended.The aim is to accomplish the goals of therapy with the least possible medication The availability of varying forms of treatment,cultural preferences,and differing health care systems need to be considered Asthma Management and Prevention Program:Summary

    展开阅读全文
    提示  163文库所有资源均是用户自行上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作他用。
    关于本文
    本文标题:支气管哮喘课件(同名22).ppt
    链接地址:https://www.163wenku.com/p-4587389.html

    Copyright@ 2017-2037 Www.163WenKu.Com  网站版权所有  |  资源地图   
    IPC备案号:蜀ICP备2021032737号  | 川公网安备 51099002000191号


    侵权投诉QQ:3464097650  资料上传QQ:3464097650
       


    【声明】本站为“文档C2C交易模式”,即用户上传的文档直接卖给(下载)用户,本站只是网络空间服务平台,本站所有原创文档下载所得归上传人所有,如您发现上传作品侵犯了您的版权,请立刻联系我们并提供证据,我们将在3个工作日内予以改正。

    163文库